用DKK678针对Nav1.5减轻了骨肌肉中NF-κB驱动的炎症损伤
Wenyao Yang1, Juanzhu Han2, Liping Zhang1
1School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
International immunopharmacology
|July 11, 2025
概括
败血症中的骨肌炎症涉及电压通道Nav1.5.5. 一种新,DKK678,针对Nav1.5减少炎症和保护器官,提供潜在的败血症治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症引起的骨肌炎症有助于结果不佳.
- 电压通道 (VGSCs) 调节免疫力,但它们在肌肉炎症中的作用尚不清楚.
- Nav1.5被研究为毒症相关的骨肌炎症的关键调节剂.
研究的目的:
- 调查Nav1.5在败血症期间骨肌肉炎症中的作用.
- 为了评估一种新的子的治疗效果,DKK678,针对Nav1.5.5.
- 阐明Nav1.5介导炎症的潜在分子机制.
主要方法:
- 建立了体外 (LPS刺激的C2C12细胞) 和体内 (小鼠的结和穿孔模型) 败血症模型.
- 评估了Nav1.5表达,NF-κB通路激活,以及炎症性细胞因子水平 (IL-6,TNF-α).
- 使用药理抑制剂 (利多卡因,TTX) 和设计DKK678进行干预.
主要成果:
- 在炎症的骨肌中,nav1.5表达被上调,与NF-κB激活和促炎细胞因子释放相关.
- DKK678有效抑制了NF-κB通路激活,减少了炎症标记物,并保护了败血症小鼠的骨肌肉和免疫器官.
- DKK678的治疗效果与德克萨米他相美,特别针对Nav1.5,但没有影响Nav1.4.
结论:
- Nav1.5是通过NF-κB通路激活在败血症中的骨肌炎症的关键调解者.
- DKK678代表了一种有前途的治疗剂,针对Nav1.5治疗败血症引起的肌肉炎和相关的炎症状况.
- Nav1.5抑制提供了一种新的治疗策略,用于控制与败血症相关的炎症.
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
767
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
767
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265


